New Warnings and Dosing Information

New warnings and dosing information have been added to Requip (ropinorole), a medication used to treat RLS and Parkinson’s disease. The makers of Requip, GlaxoSmithKline, implemented FDA approved changes in the packet insert which include updated dosage and warning information. The update indicates healthcare practitioners and patients to taper off of Requip slowly to prevent neuroleptic malignant syndrome, a potentially serious adverse reaction. Neuroleptic malignant syndrome symptoms include high fever, muscular rigidity, and autonomic dysfunction.

In the event of discontinuing Requip or augmentation, this update reflects important precautions in gradual reduction of dosage. For a highlight of prescribing information, click here.

Speak with your healthcare provider or pharmacist if you have questions regarding your medication. Do not make changes to your medication without the advise of your physician.